Sai Parenterals IPO
Sai Parenterals IPO Details
-
Open Date
24 Mar 2026
-
Close Date
27 Mar 2026
-
Listing Date
02 Apr 2026
- IPO Price Range
₹ 372 to ₹392
- IPO Size
₹ 409 Cr
- Listing Exchange
BSE, NSE
Sai Parenterals IPO Timeline
Last Updated: 21 March 2026 5:15 AM by 5paisa
Sai Parenteral's Limited is a Hyderabad-based pharmaceutical formulations company with over 30 years of experience, incorporated in 2001. It operates across two verticals - Branded Generic Formulations and Contract Development & Manufacturing Organisation (CDMO) services - spanning therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, and dermatology. The company manufactures injectables, tablets, capsules, liquid orals, and ointments across four facilities in Hyderabad, including dedicated sterile and cephalosporin units. Its CDMO arm offers end-to-end solutions covering product development, regulatory filings, and commercial manufacturing for regulated and semi-regulated global markets.
Established in: 1989
Managing Director: Anil KK
Peers:
| Name of Company | Sai Parenteral's Limited |
Sai Life Sciences Limited |
Innova Captab Limited |
Senores Pharmaceuticals Limited |
Gland Pharma Limited |
| Total Revenue (₹ Cr) | 163.1 | 169.45 | 124.37 | 398.25 | 561.65 |
|
Face Value (₹per share) |
5 | 1 | 10 | 10 | 1 |
|
Closing price on February 03, 2026 |
- | 879.15 | 727.20 | 817.65 | 1,895.70 |
| EPS Basic (₹) | 5.43 | 8.83 | 22.4 1 | 16.1 2 | 42.4 0 |
| EPS Diluted (₹) | 5.43 | 8.61 | 22.41 | 16.12 | 42.40 |
|
NAV (₹ per share) |
35.98 | 102.1 2 | 167.66 | 176.37 | 555.41 |
| P/E Ratio | - | 107.70 | 32.45 | 64.30 | 44.71 |
| RoNW (%) | 15.09 | 7.99 | 13.37 | 7.18 | 7.63 |
Sai Parenterals Objectives
1. Capacity expansion and upgradation of manufacturing facilities (₹110.8 Cr)
2. Establishment of a new R&D Centre (₹18.023 Cr)
3. Repayment / prepayment of certain outstanding borrowings (₹14.3 Cr)
4. Working capital requirements (33 Cr)
5. Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia) (₹3564.1 Cr)
6. General corporate purposes
Sai Parenteral's IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹409 Cr |
| Offer For Sale | ₹124 Cr |
| Fresh Issue | ₹285 Cr |
Sai Parenteral's IPO Lot Size
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 38 | 14,136 |
| Retail (Max) | 13 | 494 | 1,93,648 |
| S - HNI (Min) | 14 | 532 | 1,97,904 |
| S - HNI (Max) | 67 | 2,546 | 9,98,032 |
| B - HNI (Min) | 68 | 2,584 | 10,12,928 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Revenue | 97.8 | 153.8 | 163.1 |
| EBITDA | 17.64 | 31.7 | 39.4 |
| PAT | 4.4 | 8.4 | 14.5 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Total Assets | 134 | 268.1 | 272.4 |
| Share Capital | 7.2 | 13.2 | 13.3 |
| Total Liabilities | 134 | 268.1 | 272.4 |
| Cash Flows (₹ Crores) | FY23 | FY24 | FY25 |
| Net Cash Generated From / (used in) Operating Activities | -12.8 | -29.8 | 33.1 |
| Net Cash Generated From / (used in) Investing Activities | -19.0 | -46.3 | 0.44 |
| Net Cash Generated From / (used in) Financing Activities | 24 | 78.6 | -36 |
| Net Increase (Decrease) in Cash and Cash Equivalents | -7.9 | 2.5 | -2.3 |
Strengths
1. Two distinct verticals - Branded Generic Formulations and CDMO - reducing revenue concentration
2. Four manufacturing facilities in Hyderabad, including dedicated sterile and cephalosporin units
3. 30+ years of operating history with an established domestic and institutional customer base
4. Material subsidiary Revat Laboratories and foreign subsidiaries extend manufacturing and global reach
Weaknesses
1. Net revenue of ₹1,585 million in FY2025 - modest scale relative to larger pharma peers
2. Consolidated financials available only from FY2023, limiting long-term benchmarking
3. Promoter-concentrated ownership with three promoters holding majority stake
4. Hyderabad-centric facilities create geographic concentration risk
Opportunities
1. Acquisition of Noumed Pharmaceuticals opens regulated markets in Australia and New Zealand
2. Growing global CDMO outsourcing trend creates headroom for contract manufacturing growth
3. Presence across Southeast Asia, Middle East, and Africa in semi-regulated markets
4. Capacity expansion backed by a TEV report signals near-term growth investment
Threats
1. Any compliance failure can disrupt production and export approvals
2. Intense competition from larger, better-capitalised CDMO and generic pharma players
3. Integration risks associated with recent international acquisitions
4. Currency volatility could impact export revenues and input costs
1. Dual revenue model - Branded Generics and CDMO - ensures stability and diversification
2. Consistent revenue growth from ₹968 million in FY2023 to ₹1,585 million in FY2025
3. Four specialised facilities with sterile and cephalosporin manufacturing capabilities
4. Global footprint expanded via Noumed Pharmaceuticals into Australia and New Zealand
Sai Parenteral's Limited enters the public markets with a strong foundation - 30+ years of experience, four manufacturing facilities, and a dual business model spanning Branded Generic Formulations and CDMO services. With revenues growing from ₹968 million in FY2023 to ₹1,585 million in FY2025, the company demonstrates consistent momentum. Its recent acquisition of Noumed Pharmaceuticals and expanding presence across Australia, Southeast Asia, Middle East, and Africa signal clear global ambitions. Rising CDMO outsourcing demand and capacity expansion plans position Sai Parenterals well for sustained long-term growth.
- Companies
- Type
- Opening On
-
Highness Microelectronics
- SME
- 24th Mar
- Pre-Book
-
Amir Chand Jagadish Kumar Exports
- Mainboard
- 24th Mar
- Pre-Book
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Sai Parenteral's IPO opens from March 24, 2026 to March 27, 2026.
The size of Sai Parenteral's IPO is ₹409 Cr.
The price band of Sai Parenteral's IPO is fixed at ₹372 to ₹392 per share.
To apply for Sai Parenteral's IPO, follow the steps given below:
● Login to your 5paisa demat account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Sai Parenteral's IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Sai Parenteral's IPO is of 38 shares and the investment required is ₹14,136.
The share allotment date of Sai Parenteral's IPO is March 30, 2026
The Sai Parenteral's IPO will likely be listed on April 2, 2026.
Arihant Capital Markets Limited is the book running lead manager for Sai Parenteral's IPO.
Sai Parenteral's IPO plans to utilise the raised capital from the IPO for:
1. Capacity expansion and upgradation of manufacturing facilities (₹110.8 Cr)
2.Establishment of a new R&D Centre (₹18.023 Cr)
3. Repayment / prepayment of certain outstanding borrowings (₹14.3 Cr)
4. Working capital requirements (33 Cr)
5. Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia) (₹3564.1 Cr)
6. General corporate purposes
Verify Your Details
Krishca Strapping Solutions Limited
sme- Date Range 23 Oct- 27 Oct’23
- Price 200
- IPO Size 23